CARLSBAD, Calif.--(BUSINESS WIRE)--Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) today announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy designation to ION582 ...
Ultragenyx Pharmaceutical (NASDAQ:RARE) announced Saturday that GTX-102, its candidate for the rare neuro-genetic disorder Angelman syndrome, improved patient outcomes across multiple domains in a ...
WESTLAKE, Ohio — At the Achievement Centers for Children in Westlake, three-year-old Immy Synk's infectious smile lights up the room as she works through her therapy sessions. Behind that smile lies a ...
Add Yahoo as a preferred source to see more of our stories on Google. HOLLYWOOD, CALIFORNIA - MARCH 12: Colin Farrell attends the 95th Annual Academy Awards on March 12, 2023 in Hollywood, California.
Hosted on MSN
Ultragenyx’s GTX-102 Receives FDA Breakthrough Therapy Designation for Angelman Syndrome
Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) is one of the most promising stocks according to Wall Street analysts. On June 27, Ultragenyx Pharmaceutical announced that the US FDA granted Breakthrough ...
Actor Colin Farrell recently disclosed that his son, James, has Angelman syndrome, one of the driving factors behind Farrell's support for finding a cure for Angelman syndrome and for launching the ...
California Institute for Regenerative Medicine (CIRM) has awarded a $5.8 million translational research grant to a scientist at the University of California, Los Angeles (UCLA) to further support the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results